Increase in nitric oxide levels and mitochondrial membrane potential in platelets of untreated patients with major depression

Psychiatry Research

Volumn 209, Issue 3, 2013, Pages 447-452

  Moreno, Julia ^a,b   Gaspar, Enrique ^a   López Bello, Guadalupe ^a   Juárez, Eliuth ^a   Alcázar Leyva, Susana ^c   González Trujano, Eva ^a   Pavón, Lenin ^a   Alvarado Vásquez, Noé ^d  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c Instituto de Investigaciones Científicas Hans Selye   (Mexico)

^d INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Major depressive disorder; Mitochondria; Nitric oxide synthesis; Platelet mitochondrial membrane potential; Platelets

Indexed keywords

NITRIC OXIDE; PADGEM PROTEIN; SEROTONIN; TRYPTOPHAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR DEPRESSION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; PLATELET MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTONIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; TRYPTOPHAN BRAIN LEVEL;

MAJOR DEPRESSIVE DISORDER; MITOCHONDRIA; NITRIC OXIDE SYNTHESIS; PLATELET MITOCHONDRIAL MEMBRANE POTENTIAL; PLATELETS;

ADOLESCENT; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NITRIC OXIDE; P-SELECTIN; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; TRYPTOPHAN; YOUNG ADULT;

EID: 84885480855     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.12.024     Document Type: Article

References (48)

1. Alvarado-Vásquez N., Páez A., Zapata E., Alcázar-Leyva S., Zenteno E., Massó F., Montaño L.F. HUVECs from newborns with a strong family history of diabetes show diminished ROS synthesis in the presence of high glucose concentrations. Diabetes/Metabolism Research and Reviews 2007, 23:71-80.
2. Alvarado-Vásquez N., Zapata E., Alcázar-Leyva S., Massó F., Montaño L.F. Reduced NO synthesis and eNOS mRNA expression in endothelial cells from newborns with a strong family history of type 2 diabetes. Diabetes/Metabolism Research and Reviews 2007, 23:559-566.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, APA, Washington, DC. 4th ed. text revision (DSM-IV TR).
4. Anderson G.M., Feibel F.C., Cohen D.J. Determination of serotonin in whole blood, platelet-rich plasma, platelet-poor plasma and ultrafiltrate. Life Sciences 1987, 40:1063-1070.
5. André P. P-selectin in haemostasis. British Journal of Haematology 2004, 126:298-306.
6. Annie-Jeyachristy S., Geetha A., Surendran R. Changes in the level of cytosolic calcium, nitric oxide and nitric oxide synthase activity during platelet aggregation: an in vitro study in platelets from normal subjects and those with cirrhosis. Journal of Biosciences 2008, 33:45-53.
7. Baumert M., Lambert G.W., Dawood T., Lambert E.A., Esler M.D., McGrane M., Barton D., Nalivaiko E. QT interval variability and cardiac norepinephrine spillover in patients with depression and panic disorder. American Journal of Physiology Heart and Circulatory Physiology 2008, 295:H962-H968.
8. Brandacher G., Hoeller E., Fuchs D., Weiss H.G. Chronic immune activation underlies morbid obesity: is IDO a key player?. Current Drug Metabolism 2007, 8:289-295.
9. Cappelli-Bigazzi M., Battaglia C., Pannain S., Chiariello M., Ambrosio G. Role of oxidative metabolism on endothelium-dependent vascular relaxation of isolated vessels. Journal of Molecular and Cellular Cardiology 1997, 29:871-879.
10. Carneiro A.M., Blakely R.D. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. Journal of Biological Chemistry 2006, 281:24769-24780.
11. Chin J.R. Determination of six indolic compounds, including melatonin, in rat pineal using high-performance liquid chromatography with serial fluorimetric-electrochemical detection. Journal of Chromatography 1990, 528:111-121.
12. Chirkov Y.Y., Horowitz J.D. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?. Pharmacology and Therapeutics 2007, 116:287-305.
13. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., Le Mellédo J.M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biological Psychiatry 2004, 56:129-134.
14. Chrapko W., Jurasz P., Radomski M.W., Archer S.L., Newman S.C., Baker G., Lara N., Le Mellédo J.M. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006, 6:1286-1293.
15. Demyttenaere K., Bruffaerts R., Posada-Villa J., Gasquet I., Kovess V., Lepine J.P., Angermeyer M.C., Bernert S., de Girolamo G., Morosini P., Polidori G., Kikkawa T., Kawakami N., Ono Y., Takeshima T., Uda H., Karam E.G., Fayyad J.A., Karam A.N., Mneimneh Z.N., Medina-Mora M.E., Borges G., Lara C., de Graaf R., Ormel J., Gureje O., Shen Y., Huang Y., Zhang M., Alonso J., Haro J.M., Vilagut G., Bromet E.J., Gluzman S., Webb C., Kessler R.C., Merikangas K.R., Anthony J.C., Von Korff M.R., Wang P.S., Brugha T.S., Aguilar-Gaxiola S., Lee S., Heeringa S., Pennell B.E., Zaslavsky A.M., Ustun T.B., Chatterji S., WHO World Mental Health Survey Consortium, et al. WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. Journal of the American Medical Association 2004, 291:2581-2590.
16. Dhir A., Kulkarni S.K. Nitric oxide and major depression. Nitric Oxide 2011, 24:125-131.
17. Doornbos B., Fekkes D., Tanke M.A., de Jonge P., Korf J. Sequential serotonin and noradrenalin associated processes involved in postpartum blues. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1320-1325.
18. Gigliucci V., Buckley K.N., Nunan J., O'Shea K., Harkin A. A role for serotonin in the antidepressant activity of NG-Nitro-l-arginine, in the rat forced swimming test. Pharmacology, Biochemistry, and Behavior 2010, 94:524-533.
19. González-Trujano M.E., Alvarado-Vásquez N., Mendoza-Sotelo J., López G., Estrada-Camarena E., Martínez-Mota L., Moreno J. Alterations on the morphology, nitric oxide synthesis and activity of platelets reproduced in rats as possible biomarkers for depression are reversed by fluoxetine. Pharmacology, Biochemistry, and Behavior 2012, 102:349-356.
20. Guo X., Wu J., Du J., Ran J., Xu J. Platelets of type 2 diabetic patients are characterized by high ATP content and low mitochondrial membrane potential. Platelets 2009, 20:588-593.
21. Halperin D., Reber G. Influence of antidepressants on hemostasis. Dialogues in Clinical Neuroscience 2007, 9:47-59.
22. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967, 6:278-296.
23. Harkin A., Connor T.J., Walsh M., John N., Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003, 44:616-623.
24. Harkin A., Connor T.J., Burns M.P., Kelly J.P. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. European Neuropsychopharmacology 2004, 14:274-281.
25. Heinze, G., 2000. Mini International Neuropsychiatric Interview. Spanish and Central American Version. DSM-IV. Sheehan DV and Lecrubier Y.
26. Ikenouchi-Sugita A., Yoshimura R., Hori H., Umene-Nakano W., Ueda N., Nakamura J. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33:1451-1453.
27. Kitzlerová E., Anders M. The role of some new factors in the pathophysiology of depression and cardiovascular disease: overview of recent research. Neuroendocrinology Letters 2007, 28:832-840.
28. Krass M., Wegener G., Vasar E., Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behavioural Brain Research 2011, 218:57-63.
29. Leaver H.A., Schou A.C., Rizzo M.T., Prowse C.V. Calcium-sensitive mitochondrial membrane potential in human platelets and intrinsic signals of cell death. Platelets 2006, 17:368-377.
30. Medina-Urrutia A., Juarez-Rojas J.G., Martínez-Alvarado R., Jorge-Galarza E., Posadas-Sánchez R., Cardoso-Saldaña G., Caracas-Portilla N., Mendoza-Perez E., Posadas-Romero C. High-density lipoprotein subclasses distribution and composition in Mexican adolescents with low HDL cholesterol and/or high triglyceride concentrations, and its association with insulin and C-reactive protein. Atherosclerosis 2008, 201:392-397.
31. Mendoza-Sotelo J., Torner C., Alvarado-Vásquez N., Lazo-Langner A., López G., Arango I., Pavón L., González-Trujano E., Moreno J. Ultrastructural changes and immunolocalization of P-selectin in platelets from patients with major depression. Psychiatry Research 2010, 176:179-182.
32. Miura H., Ozaki N., Sawada M., Isobe K., Ohta T., Nagatsu T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008, 11:198-209.
33. Nair G.V., Gurbel P.A., O'Connor C.M., Gattis W.A., Murugesan S.R., Serebruany V.L. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. American Journal of Cardiology 1999, 84:321-323.
34. Nemeroff C.B., Musselman D.L. Are platelets the link between depression and ischemic heart disease?. American Heart Journal 2000, 140:S57-S62.
35. Parakh K., Sakhuja A., Bhat U., Ziegelstein R.C. Platelet function in patients with depression. Southern Medical Journal 2008, 101:612-617.
36. Piletz J.E., Halaris A., Iqbal O., Fareed D., Hoppensteadt D., Fareed J., Zhu H., Sinacore J., DeVane C.L. Nitric oxide branch of arginine metabolism in depression: effect of venlafaxine. International Journal of Health Sciences 2009, 2:274-281.
37. Rajendran S., Chirkov Y.Y. Platelet hyperaggregability: impaired responsiveness to nitric oxide (platelet NO resistance) as a therapeutic target. Cardiovascular Drugs and Therapy 2008, 22:193-203.
38. Shi C., Guo K., Yew D.T., Yao Z., Forster E.L., Wang H., Xu J. Effects of ageing and Alzheimer's disease on mitochondrial function of human platelets. Experimental Gerontology 2008, 6:589-594.
39. Skala J.A., Freedland K.E., Carney R.M. Coronary heart disease and depression: a review of recent mechanistic research. Canadian Journal of Psychiatry 2006, 51:738-745.
40. Stokes P.E. The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. European Neuropsychopharmacology 1995, 5(Suppl):77-82.
41. Suzuki E., Yagi G., Nakaki T., Kanba S., Asai M. Elevated plasma nitrate levels in depressive states. Journal of Affective Disorders 2001, 63:221-224.
42. Valles V., Aguilar-Salinas C.A., Gómez-Pérez F.J., Rojas R., Franco A., Olaiz G., Rull J.A., Sepulveda J. Apolipoprotein B and A-I distribution in Mexican urban adults: results of a nationwide survey. Metabolism: Clinical and Experimental 2002, 51:560-568.
43. Verhoeven A.J., Verhaar R., Gouwerok E.G., de Korte D. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005, 45:82-89.
44. Vignini A., Nanetti L., Moroni C., Testa R., Sirolla C., Marra M., Cenerelli S., Gregori A., Fumelli D., Olivieri F., Mazzanti L., Rabini R.A. Platelet nitric oxide production and IR: Relation with obesity and hypertriglyceridemia. Nutrition, Metabolism, and Cardiovascular Diseases 2008, 18:553-558.
45. Wang D., An S.C., Zhang X. Prevention of chronic stress-induced depression-like behavior by inducible nitric oxide inhibitor. Neuroscience Letters 2008, 433:59-64.
46. Washizuka S., Kametani M., Sasaki T., Tochigi M., Umekage T., Kohda K., Kato T. Association of mitochondrial complex I subunit geneNDUFV2 at 18p11 with schizophrenia in the Japanese population. American Journal of Medical Genetics: Part B, Neuropsychiatric Genetics 2006, 141B:301-304.
47. Watanabe R., Kishi Y., Sakita S., Numano F. Impaired NO release from bovine aortic endothelial cells exposed to activated platelets. Atherosclerosis 1997, 128:19-26.
48. Yanik M., Vural H., Tutkun H., Zoroglu S.S., Savas H.A., Herken H., Koçyiǧit A., Keleş H., Akyol O. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. European Archives of Psychiatry and Clinical Neuroscience 2004, 254:43-47.